SPOTLIGHT: FDA extends Doribax review


The FDA is extending its review of Johnson & Johnson's Doribax for pneumonia by three months. Regulators say the company has provided new information about the drug that needs to be assessed. Release

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.